No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Ganetespib is a small molecule inhibitor of the heat shock protein 90 (Hsp90) that is used to treat non-small cell lung cancer (NSCLC). It is a targeted therapy that works by blocking the activity of Hsp90, which is a protein that helps cancer cells survive and grow. Ganetespib is used in combination with other chemotherapy drugs to treat NSCLC that has spread to other parts of the body. It is also used to treat NSCLC that has not responded to other treatments.
Ganetespib is a relatively new drug and is still in the early stages of development. It is being studied in clinical trials to determine its safety and effectiveness in treating NSCLC. The drug has shown promise in early studies, but more research is needed to determine its long-term efficacy.
The Ganetespib market is a rapidly growing one, with many companies investing in research and development of the drug. Companies such as Genentech, Merck, and AstraZeneca are all involved in the development of Ganetespib. Other companies such as Novartis, Pfizer, and Bristol-Myers Squibb are also researching the drug and its potential uses. Show Less Read more
